IFNA1 and Cirrhosis: However, enthusiasm for treating patients with cirrhosis is somewhat limited by the still disappointing SVR rates that are achieved in this group of patients by interferon (IFN)-based regimens, as well as by the risk of developing serious treatment related adverse events (AEs), which are especially worrisome in some categories of patients such as those with a decompensated disease [11][12].